NEW YORK – Sophia Genetics said Thursday that it is collaborating with AstraZeneca to help European laboratories and research institutions conduct in-house testing for homologous recombination deficiency in ovarian cancer.
The collaboration will center around Sophia's newly released, deep learning-based application on its Data-Driven Medicine (DDM) platform for HRD detection. The app, also introduced Thursday, combines identification of HRD-causing mutations with analysis of HRD-induced genomic instability across tumor genomes to inform cancer research.
"Providing laboratories with innovative solutions to enable locally delivered HRD testing is critically important, particularly in settings such as advanced ovarian cancer, where approximately half of all newly diagnosed patients have HRD-positive tumors," Kristina Rodnikova, senior VP of global oncology diagnostics at AstraZeneca, said in a statement.
Switzerland-based Sophia said that its new DDM HRD product decentralizes HRD testing of tumor samples, enabling end users to access Sophia's genomic analysis while retaining ownership of their data.
"Our Sophia DDM HRD solution will provide researchers and other healthcare professionals with a decentralized approach to fully integrated HRD testing, enabling the HRD status of more advanced ovarian cancer cases to be determined without reliance on send-out testing solutions," Sophia cofounder and CEO Jurgi Camblong said.